Alixo-Yolloo Corp. - 8-K

Item 7.01 Regulation FD Disclosure

On March 23, 2026, Made in USA Inc. (the “Company”) executed
a non-binding term sheet (the “Term Sheet”) with Rosalind, Inc. (“Rosalind”) outlining the principal terms of
a proposed transaction involving the formation of a new operating entity, Rosalind Systems, Inc.

On March 31, 2026, the Company issued a press release announcing the
execution of the Term Sheet and describing the proposed transaction with Rosalind.

A copy of the press release is furnished as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated herein by reference.

The information furnished pursuant to this Item 7.01, including Exhibit
99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities under that Section, and shall not be deemed incorporated by reference into any filing under the Securities
Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 8.01 Other Events

The previously defined Term Sheet provides a framework under which
Rosalind is expected to contribute certain platform assets and intellectual property to Rosalind Systems, Inc., which is intended to serve
as a platform for growth initiatives at the intersection of healthcare, life sciences, and data infrastructure. The proposed transaction
contemplates the integration of the Company’s data wallet and certification technologies with Rosalind’s existing platform.

The Term Sheet also contemplates that Rosalind Systems, Inc. would
be structured to support capital formation and expansion into areas including biopharma and biotech research, clinical and translational
data, consumer health and wellness, and public health infrastructure.

The Term Sheet is non-binding, except for customary provisions such
as confidentiality and exclusivity, and is subject to the negotiation and execution of definitive agreements, completion of financing,
and satisfaction of other customary closing conditions. There can be no assurance that definitive agreements will be executed or that
the proposed transaction will be completed on the terms described in the Term Sheet or at all.

The foregoing description of the Term Sheet does not purport
to be complete and is qualified in its entirety by reference to the full text of the Term Sheet, which the Company may file as an exhibit
to a future report if and when required.

Item
9.01 Financial Statements and Exhibits

(d)       Exhibits

Exhibit No.

Description

99.1

Press Release Dated March 31, 2026

104

Cover Page Interactive Data File (formatted in iXBRL, and included in exhibit 101)

2